Benefits Reviews
Codes and Coverage
Supporting patient access
BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.
Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
ONUREG®
(azacitidine) tablets
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
National Drug Codes (NDC)1
Issued by the FDA
Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
| 59572-0730-07 | 200-mg tablets; one blister card containing 7 tablets |
| 59572-0740-07 | 300-mg tablets; one blister card containing 7 tablets |
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)2
| C92 | Myeloid leukemia† |
| C92.0 | Acute myeloblastic leukemia† |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.01 | Acute myeloblastic leukemia, in remission |
| C92.5 | Acute myelomonocytic leukemia† |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.51 | Acute myelomonocytic leukemia, in remission |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality† |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality, not having achieved remission |
| C92.61 | Acute myeloid leukemia with 11q23-abnormality, in remission |
| C92.A | Acute myeloid leukemia with multilineage dysplasia† |
| C92.A0 | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A1 | Acute myeloid leukemia with multilineage dysplasia, in remission |
| C92.Z | Other myeloid leukemia† |
| C92.Z0 | Other myeloid leukemia, not having achieved remission |
| C92.Z1 | Other myeloid leukemia, in remission |
| C92.9 | Myeloid leukemia, unspecified† |
| C92.90 | Myeloid leukemia, unspecified, not having achieved remission |
| C92.91 | Myeloid leukemia, unspecified, in remission |
| C93 | Monocytic leukemia† |
| C93.0 | Acute monoblastic/monocytic leukemia† |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.01 | Acute monoblastic/monocytic leukemia, in remission |
| C94 | Other leukemias of specified cell type† |
| C94.0 | Acute erythroid leukemia† |
| C94.00 | Acute erythroid leukemia, not having achieved remission |
| C94.01 | Acute erythroid leukemia, in remission |
| C94.2 | Acute megakaryoblastic leukemia† |
| C94.20 | Acute megakaryoblastic leukemia, not having achieved remission |
| C94.21 | Acute megakaryoblastic leukemia, in remission |
*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.
†This is a category code and is invalid for stand-alone use. Please use the expanded code listed below.
Please see U.S. Full Prescribing Information for ONUREG.
References:
- ONUREG (azacitidine) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm. Accessed August 2, 2023.
The following distributors are authorized to sell ONUREG and are able to service qualified accounts.
Physician Offices
| Specialty Distributor | Phone & Fax Orders |
| Cardinal Health Specialty Pharmaceutical Distribution > | Phone: 1-877‑453‑3972
|
| CuraScript Specialty Distribution > | Phone: 1‑877‑599‑7748
|
| McKesson Specialty Health > | Phone: 1‑800‑482‑6700
|
| Morris & Dickson Specialty > | Phone: 1‑800‑710‑6100
Fax: 1‑318‑524‑3096
|
| Oncology Supply > | Phone: 1‑800‑633‑7555
|
Hospitals and Infusion Centers
| Specialty Distributor | Phone & Fax Orders |
| ASD Healthcare > | Phone: 1-800-746-6273
Fax: 1-800-547-9413
|
| Cardinal Health Specialty Pharmaceutical Distribution > | Phone: 1-866-677-4844
Fax: 1-614-553-6301
|
| McKesson Plasma and Biologics > | Phone: 1-877-625-2566
Fax: 1-888-752-7626
|
| Morris & Dickson Specialty > | Phone: 1-800-710-6100
Fax: 1-318-524-3096
|
Puerto Rico Hospitals and Clinics
| Authorized Distributor | Phone & Fax Orders |
| AmerisourceBergen Puerto Rico > | Phone: 1-844-222-2273 |
| Cardinal Puerto Rico (Borschow) > | Phone: 1-787-625-4200
|
| Cesar Castillo, Inc. > | Phone: 1-787-641-5242 (Hospitals)
Phone: 1-787-641-5082 (Specialty Pharmacies)
Fax: 1-787-999-1614
|
Above information is accurate as of 01/26.
ONUREG is available through external specialty pharmacies. Please check with your patient's insurance plan for the appropriate specialty pharmacy.
ONUREG can also be procured by the practice directly from one of the authorized distributors in the list above. Please ensure your practice has the durable medical equipment (DME) license in place to bill the appropriate DME Medicare Administrative Contractor (DME MAC).
Please see U.S. Full Prescribing Information for ONUREG.
FDA Approval Letter as Posted by the FDA:
ONUREG for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy – Approved on 09/01/2020
Please see U.S. Full Prescribing Information for ONUREG.
See Payer Policy Details
Learn about payer information by state for applicable treatments.
